CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-17). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 430 · Search date 2026-07-17 · Methodology v0.6

Meso-zeaxanthin,
does it really help with Increased macular pigment, improved contrast sensitivity, and reduced glare disability?

30-Second Summary
C
Evidence Grade C · 46 · Safety acceptable
The combination increases macular pigment, but the independent added value of meso-zeaxanthin remains unclear
What the
research shows
Combinations of lutein, zeaxanthin, and meso-zeaxanthin have increased macular pigment optical density and improved some contrast-sensitivity and glare measures in randomized trials. Meso-zeaxanthin, however, was almost always administered in a combination. In a direct 121-person AMD trial, improvements were similar with and without adding 10 mg of meso-zeaxanthin. Its independent contribution is unclear, so the grade is C.
What the
ads claim
Descriptions such as 'the third carotenoid that fills the center of the macula,' 'stronger than lutein for glare,' or 'an upgraded AREDS2' run ahead of direct comparisons. AREDS2 did not test meso-zeaxanthin, and combination results should not be advertised as a stand-alone ingredient effect.
*

Useful facts when choosing a product

  • Common study formulations used 10 mg lutein, 2 mg zeaxanthin, and 10 mg meso-zeaxanthin per day, or other ratios of all three carotenoids.
  • Products sold in Korea and abroad are usually lutein-zeaxanthin combinations rather than stand-alone meso-zeaxanthin.
  • Responses can vary with the macular-pigment method, baseline pigment, and oil or micellar formulation.
  • Serious safety signals were uncommon in trials, but long-term stand-alone meso-zeaxanthin data are sparser than combination-product data.
Gap Measurement · Verdict 430 · C 46
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The 36-person Loughman trial reported improved macular pigment and visual function in the lutein-zeaxanthin-meso-zeaxanthin group, but the sample was small and all three carotenoids were given together. The 44-person Connolly placebo-controlled trial also assessed serum and macular responses to a three-carotenoid combination. In the 121-person Akuffo AMD trial, both AREDS2-type combinations improved contrast sensitivity, glare measures, and macular pigment, but results were comparable between the group with an additional 10 mg of meso-zeaxanthin and the group without it. A 2016 meta-analysis of 20 trials found that macular carotenoids increased macular pigment and that increases appeared larger in trials containing meso-zeaxanthin, but it could not isolate ingredient-level causality.

02

Why this is classified as C (46)

Combination randomized trials and meta-analysis support macular-pigment and some visual-function signals, but the direct add-on comparison was negative and independent contribution cannot be separated. Surrogate endpoints and combination attribution yield C with 52 points.

Counterpoint. Combinations containing meso-zeaxanthin have been studied as one macular-carotenoid strategy, but stand-alone superiority is unproven.

Rejudgment record. New verdict — Positive macular-pigment and visual-function trials of combinations containing meso-zeaxanthin, but no benefit in a direct add-on comparison and unclear independent contribution

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Increase in macular pigment optical densityCRepeated with combinations containing meso-zeaxanthin, but it is a surrogate and ingredient-level contribution is not isolated.
Improvement in contrast sensitivity and glare disabilityCPositive combination trials exist, but a direct comparison found no difference between formulations with and without added meso-zeaxanthin.
Added benefit of meso-zeaxanthin over an AREDS2-type formulationDA 121-person direct randomized comparison found no between-group added benefit in primary or secondary visual function or macular pigment.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Loughman J et al. 2012Single-masked randomized placebo-controlled trial36Possible industry linksMacular pigment, visual acuity, contrast sensitivity, and glareSome macular-pigment and visual-function measures improved only in the lutein-zeaxanthin-meso-zeaxanthin group; small combination trial.Supportive
Akuffo KO et al. 2017Randomized double-blind head-to-head trial121Branded formulations and investigator industry linksContrast sensitivity, glare disability, macular pigment, and reading speedBoth groups improved, but there was no between-group difference with versus without an additional 10 mg of meso-zeaxanthin.Key
Ma L et al. 2016Systematic review and meta-analysis of randomized trials826UnknownMacular pigment optical densityMacular carotenoids increased macular pigment; trials containing meso-zeaxanthin appeared larger, but this was an indirect comparison of combinations.Key
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-17).

Loughman J, Nolan JM, Howard AN, Connolly E, Meagher K, Beatty S. The impact of macular pigment augmentation on visual performance using different carotenoid formulations. Invest Ophthalmol Vis Sci. 2012;53(12):7871-7880. PMID: 23132800. DOI: 10.1167/iovs.12-10690.
checked
Akuffo KO, Beatty S, Peto T, et al. The impact of supplemental antioxidants on visual function in nonadvanced age-related macular degeneration: a head-to-head randomized clinical trial. Invest Ophthalmol Vis Sci. 2017;58(12):5347-5360. PMID: 29053808. DOI: 10.1167/iovs.16-21192.
checked
Ma L, Liu R, Du JH, Liu T, Wu SS, Liu XH. Lutein, zeaxanthin and meso-zeaxanthin supplementation associated with macular pigment optical density. Nutrients. 2016;8(7):426. PMID: 27420092. DOI: 10.3390/nu8070426.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-17 · Corrections: none

Cite this verdict

Meso-zeaxanthin x macular pigment, contrast sensitivity, and glare Evidence Grade C card
[Chamgap] Meso-zeaxanthin x macular pigment, contrast sensitivity, and glare — Evidence Grade C·46. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/eye/meso-zeaxanthin-macular-pigment-contrast-glare/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.